JO3152B1 - Glycoside derivatives and uses thereof - Google Patents

Glycoside derivatives and uses thereof

Info

Publication number
JO3152B1
JO3152B1 JOP/2010/0359A JOP20100359A JO3152B1 JO 3152 B1 JO3152 B1 JO 3152B1 JO P20100359 A JOP20100359 A JO P20100359A JO 3152 B1 JO3152 B1 JO 3152B1
Authority
JO
Jordan
Prior art keywords
glycoside derivatives
diseases
treating
conditions
sglt
Prior art date
Application number
JOP/2010/0359A
Other languages
Arabic (ar)
Inventor
Kashinath Hajare Atul
Venkata Palle P
Raymond Bebernitz Gregory
Liang Jessica
Srinivas Reddy Dumbala
Bhuniya Debnath
Bhausaheb Bhosale Sandeep
Eknath Kurhade Suresh
Salunkhe Videsh
Vyavahare Vinod
Feng Lili
G Bock Mark
S Shaikh Nadim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3152(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3152B1 publication Critical patent/JO3152B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

This invention relates to compounds represented by formula (I):‎ ‎(I)‎ wherein the variables are defined as herein above, which are useful for treating diseases ‎and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. ‎The invention also provides methods of treating such diseases and conditions, and ‎compositions etc. for their treatment.‎
JOP/2010/0359A 2009-10-20 2010-10-20 Glycoside derivatives and uses thereof JO3152B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2173DE2009 2009-10-20
IN2689DE2009 2009-12-23

Publications (1)

Publication Number Publication Date
JO3152B1 true JO3152B1 (en) 2017-09-20

Family

ID=43216622

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0359A JO3152B1 (en) 2009-10-20 2010-10-20 Glycoside derivatives and uses thereof

Country Status (39)

Country Link
US (7) US8163704B2 (en)
EP (1) EP2491029B1 (en)
JP (2) JP5384744B2 (en)
KR (2) KR101465308B1 (en)
CN (1) CN102656165B (en)
AR (1) AR078685A1 (en)
AU (1) AU2010309833B2 (en)
BR (1) BR112012009053B1 (en)
CA (1) CA2777812C (en)
CL (1) CL2012000991A1 (en)
CO (1) CO6531486A2 (en)
CR (1) CR20120176A (en)
CU (1) CU24079B1 (en)
CY (1) CY1117409T1 (en)
DK (1) DK2491029T3 (en)
EA (1) EA023781B1 (en)
EC (1) ECSP12011909A (en)
ES (1) ES2564191T3 (en)
GT (1) GT201200117A (en)
HK (1) HK1168099A1 (en)
HN (1) HN2012000798A (en)
HR (1) HRP20160436T1 (en)
HU (1) HUE027531T2 (en)
IL (1) IL219309A (en)
JO (1) JO3152B1 (en)
MA (1) MA33737B1 (en)
MX (1) MX2012004700A (en)
MY (1) MY158326A (en)
NZ (1) NZ598717A (en)
PE (1) PE20121281A1 (en)
PL (1) PL2491029T3 (en)
RS (1) RS54563B1 (en)
SG (1) SG179562A1 (en)
SI (1) SI2491029T1 (en)
TN (1) TN2012000109A1 (en)
TW (2) TWI594756B (en)
UY (1) UY32958A (en)
WO (1) WO2011048112A1 (en)
ZA (1) ZA201201680B (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011009824A (en) 2009-03-23 2012-01-25 Glenmark Pharmaceuticals Sa Fused pyrimidine-dione derivatives as trpa1 modulators.
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
US8163704B2 (en) * 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
CN102134226B (en) * 2010-01-26 2013-06-12 天津药物研究院 Phenyl C-glucoside derivatives, preparation method and use thereof
HUE029853T2 (en) 2010-05-11 2017-04-28 Janssen Pharmaceutica Nv Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienylmethylbenzene derivatives as inhibitors of sglt
CA2832938C (en) 2011-04-13 2019-09-03 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
US8614195B2 (en) * 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
BR112013026361A2 (en) 2011-04-14 2016-12-27 Novartis Ag glycoside derivatives and uses thereof
US9035044B2 (en) * 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
ES2719656T3 (en) 2011-06-01 2019-07-11 Green Cross Corp Novel diphenylmethane derivatives as SGLT2 inhibitors
CN102827122B (en) * 2011-06-17 2015-01-14 山东轩竹医药科技有限公司 Glucoside derivate
CN102863417B (en) * 2011-07-09 2015-01-14 山东轩竹医药科技有限公司 C-indican derivative
TWI589576B (en) * 2011-07-15 2017-07-01 諾華公司 Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors
AR087701A1 (en) * 2011-08-31 2014-04-09 Japan Tobacco Inc PIRAZOL DERIVATIVES WITH SGLT1 INHIBITING ACTIVITY
UA113086C2 (en) 2012-05-10 2016-12-12 PRAZOLE COMPOUNDS AS SGLT1 INHIBITORS
CN105007914A (en) * 2013-03-11 2015-10-28 詹森药业有限公司 Dual SGLT1/SGLT2 inhibitors
WO2014203217A1 (en) 2013-06-21 2014-12-24 Lupin Limited Substituted heterocyclic compounds as crac modulators
WO2014207648A1 (en) 2013-06-24 2014-12-31 Lupin Limited Chromane and chromene derivatives and their use as crac modulators
CN104250272B (en) * 2013-06-27 2018-10-09 上海方楠生物科技有限公司 A method of it is prepared using microreactor and arranges net class pharmaceutical intermediate
AU2014317663B2 (en) * 2013-09-09 2018-02-08 Youngene Therapeutics Co., Ltd. C-aryl glucoside derivative, preparation method for same, and medical applications thereof
AR098670A1 (en) 2013-11-08 2016-06-08 Lilly Co Eli SGLT1 INHIBITOR
CN104017031A (en) * 2014-06-21 2014-09-03 李友香 Hypoglycemic drug and composition
CN104031098A (en) * 2014-06-21 2014-09-10 李友香 Hypoglycemic medicine
CN105294624B (en) * 2015-11-16 2018-01-12 山东罗欣药业集团股份有限公司 A kind of preparation method of Dapagliflozin
HRP20211670T8 (en) 2016-06-17 2022-03-18 Daewoong Pharmaceutical Co., Ltd. Diphenylmethane derivative in crystalline form
US10815210B2 (en) 2016-11-10 2020-10-27 Janssen Pharmaceutica Nv Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators
CN108203432B (en) * 2016-12-20 2021-03-02 宜昌东阳光长江药业股份有限公司 Glucopyranosyl derivative and application thereof in medicine
AR111161A1 (en) 2017-03-03 2019-06-12 Novartis Ag DOSAGE SCHEME FOR THE SGLT1 / 2 INHIBITOR (LICOGLIFLOZIN)
WO2018189671A1 (en) * 2017-04-12 2018-10-18 Novartis Ag Use of lik066 in heart failure patients
JP2020524684A (en) * 2017-06-21 2020-08-20 ノバルティス アーゲー Lycofrigosine for the treatment of non-alcoholic steatohepatitis
US10696662B2 (en) 2017-08-21 2020-06-30 Janssen Pharmaceutica Nv 5-fluoro-C-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators
GB201721960D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721961D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721964D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721967D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721957D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
MA53388A (en) 2018-07-25 2021-06-02 Novartis Ag NLRP3 INHIBITORS OF INFLAMMASOME
CN108863736A (en) * 2018-07-27 2018-11-23 福州大学 A kind of preparation method of the aromatic carboxylic acids of carbonyl functionalization
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
WO2020151623A1 (en) * 2019-01-24 2020-07-30 北京盈科瑞创新药物研究有限公司 Compound, preparation method therefor, and medical uses of intermediate thereof
WO2020151620A1 (en) * 2019-01-24 2020-07-30 北京盈科瑞创新药物研究有限公司 Compound, and preparation method therefor and application thereof as drug intermediate
AR119731A1 (en) 2019-05-17 2022-01-05 Novartis Ag NLRP3 INFLAMASOME INHIBITORS
KR20220038368A (en) 2019-07-23 2022-03-28 노파르티스 아게 Combination treatment of liver disease with FXR agonists
CN111099975A (en) * 2019-12-23 2020-05-05 河北合佳医药科技集团股份有限公司 Preparation method of 5-bromo-2-chloro-4' -ethoxy benzophenone
WO2022105845A1 (en) * 2020-11-19 2022-05-27 北京盈科瑞创新药物研究有限公司 Glucoside derivative, and preparation method therefor and application thereof
TW202406550A (en) 2022-08-03 2024-02-16 瑞士商諾華公司 Nlrp3 inflammasome inhibitors

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (en) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 Fastening element
US5410031A (en) * 1992-02-24 1995-04-25 The Regents Of The University Of California Office Of Technology Transfer Nucleoside cotransporter protein cDNA
US5410054A (en) 1993-07-20 1995-04-25 Merck Frosst Canada, Inc. Heteroaryl quinolines as inhibitors of leukotriene biosynthesis
WO1998031697A1 (en) 1997-01-15 1998-07-23 Sankyo Company, Limited Aryl c-glycoside compounds and sulfated esters thereof
KR100591585B1 (en) 1999-08-31 2006-06-20 깃세이 야쿠힌 고교 가부시키가이샤 Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
JP4272319B2 (en) * 1999-11-30 2009-06-03 アイシン精機株式会社 Headrest device
US6627611B2 (en) * 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
JP4456768B2 (en) 2000-02-02 2010-04-28 壽製薬株式会社 Drug containing C-glycoside
RU2254340C2 (en) 2000-03-17 2005-06-20 Киссеи Фармасьютикал Ко., Лтд. Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions comprising these derivatives and intermediate compounds for preparing indicated derivatives
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
IL155071A0 (en) 2000-09-29 2003-10-31 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medical compositions containing the same
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
WO2002080936A1 (en) * 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
CA2443325C (en) 2001-04-04 2011-06-14 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
EP1432720A1 (en) 2001-09-05 2004-06-30 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
DE10231370B4 (en) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophene glycoside derivatives, medicaments containing these compounds and methods of making these medicaments
JP2004137245A (en) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd Pyrazole derivative, pharmaceutical composition containing the same, its pharmaceutical use and production intermediate
CA2507665A1 (en) 2002-12-04 2004-06-17 Kissei Pharmaceutical Co., Ltd. Preventive or remedy for diseases caused by hyperglycemia
DE10258008B4 (en) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclic fluoroglycoside derivatives, medicaments containing these compounds and methods of making these medicaments
DE10258007B4 (en) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatic fluoroglycoside derivatives, medicaments containing these compounds and methods for the preparation of these medicaments
EP1444890B1 (en) 2003-02-05 2009-01-07 Hermann Koepsell RS1 deficient transgenic animal and uses thereof
KR101001848B1 (en) * 2003-03-14 2010-12-17 고토부키 세이야쿠 가부시키가이샤 C-glycoside derivatives and salts thereof, and a pharmaceutical composition comprising the same
AU2003902263A0 (en) 2003-05-12 2003-05-29 Fujisawa Pharmaceutical Co., Ltd. Monosaccharide compounds
PT1651658E (en) * 2003-08-01 2013-03-07 Mitsubishi Tanabe Pharma Corp Novel compounds having inhibitory activity against sodium-dependant transporter
WO2005011592A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indazole-o-glucosides
CA2539032A1 (en) 2003-08-26 2005-03-10 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pirazoles, drugs containing said compounds the use and production method thereof
KR101141558B1 (en) 2004-03-04 2012-05-03 깃세이 야쿠힌 고교 가부시키가이샤 Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
JP5078350B2 (en) 2004-03-04 2012-11-21 キッセイ薬品工業株式会社 Fused heterocyclic derivative, pharmaceutical composition containing the same, and pharmaceutical use thereof
DE102004028241B4 (en) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh New fluoroglycoside derivatives of pyrazoles, medicines containing these compounds and manufacture of these medicines
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
DE102004034690A1 (en) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methylidene-D-xylopyranosyl and oxo-D-xylopyranosyl-substituted phenyls, medicaments containing these compounds, their use and processes for their preparation
EP1773800A1 (en) * 2004-07-27 2007-04-18 Boehringer Ingelheim International GmbH D-glucopyranosyl phenyl-substituted cyclene, medicaments containing these compounds, their use, and method for the production thereof
WO2006018150A1 (en) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituited cyclene, medicaments containing said compounds, use thereof and method for the production thereof
CA2577632C (en) 2004-09-22 2014-04-01 Soraya Shirazi-Beechey Intestinal epithelial glucose sensor
DE102004048388A1 (en) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-pyranosyl-substituted phenyls, pharmaceutical compositions containing them, their use and processes for their preparation
US7750145B2 (en) 2004-11-18 2010-07-06 Kissei Pharmaceutical Co., Ltd. 1-substituted-3-β-D-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same
UA91546C2 (en) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Crystalline form of 1-chloro-4-(я-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
WO2007140191A2 (en) * 2006-05-23 2007-12-06 Theracos, Inc. Glucose transport inhibitors and methods of use
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
WO2008115574A1 (en) 2007-03-21 2008-09-25 Reliant Pharmaceuticals, Inc. Cb1 antagonist and a dyslipidemic agent and/or metabolic regulator, and methods of making and using same
TW200904454A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
WO2008131224A2 (en) 2007-04-18 2008-10-30 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
EP2197433A4 (en) 2007-08-20 2010-09-08 Sinai School Medicine Regulating glp-1 and sglt-1 in gastrointestinal cells
PL2187742T3 (en) 2007-08-23 2018-06-29 Theracos Sub, Llc (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylphenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol derivatives for use in the treatment of diabetes
CL2008003653A1 (en) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Use of a glucopyranosyl-derived sglt inhibitor and a selected dppiv inhibitor to treat diabetes; and pharmaceutical composition.
CN101969944B (en) * 2008-01-31 2013-04-10 安斯泰来制药有限公司 Pharmaceutical composition for treatment of fatty liver diseases
BRPI0913129A2 (en) 2008-05-22 2016-01-05 Bristol Myers Squibb Co method for treating hyperuricemia employing an sglt2 inhibitor and composition containing the same
WO2009143010A1 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating hyponatremia employing an sglt2 inhibitor and composition containing same
WO2009143021A1 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating and preventing kidney stones employing an sglt2 inhibitor and composition containing same
CN102159206A (en) 2008-09-19 2011-08-17 诺瓦提斯公司 Glucoside derivatives and uses thereof as sglt inhibitors
BRPI0919411A2 (en) 2008-09-19 2015-12-15 Novartis Ag glycoside derivative and uses thereof
WO2010045656A2 (en) 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
WO2010048358A2 (en) 2008-10-22 2010-04-29 Auspex Pharmaceutical, Inc. Ethoxyphenylmethyl inhibitors of sglt2
WO2010074219A1 (en) 2008-12-26 2010-07-01 アステラス製薬株式会社 Benzothiophen compound
US20120035105A1 (en) 2009-01-09 2012-02-09 Sdg, Inc. Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
CN104906582A (en) 2009-02-13 2015-09-16 勃林格殷格翰国际有限公司 Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof
MA33043B1 (en) 2009-02-13 2012-02-01 Boehringer Ingelheim Int Sglt-2 inhibitor for type 1 diabetes, type 2 diabetes, glucose imbalance or hyperglycemia
WO2010128152A1 (en) * 2009-05-07 2010-11-11 Novartis Ag Fused heterocyclic c-glycosides for the treatment of diabetes
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof

Also Published As

Publication number Publication date
HK1168099A1 (en) 2012-12-21
AU2010309833B2 (en) 2014-06-12
ES2564191T3 (en) 2016-03-18
HN2012000798A (en) 2015-08-03
JP5384744B2 (en) 2014-01-08
AU2010309833A1 (en) 2012-03-29
US20170042925A1 (en) 2017-02-16
DK2491029T3 (en) 2016-04-11
IL219309A (en) 2015-03-31
GT201200117A (en) 2013-09-23
US9895389B2 (en) 2018-02-20
TN2012000109A1 (en) 2013-09-19
CY1117409T1 (en) 2017-04-26
MX2012004700A (en) 2012-05-23
EA023781B1 (en) 2016-07-29
HUE027531T2 (en) 2016-10-28
CN102656165A (en) 2012-09-05
US20140274921A1 (en) 2014-09-18
ZA201201680B (en) 2012-11-28
JP2014040451A (en) 2014-03-06
US8828951B2 (en) 2014-09-09
BR112012009053A2 (en) 2016-04-19
TWI558723B (en) 2016-11-21
PL2491029T3 (en) 2016-07-29
EA201200600A1 (en) 2012-12-28
US8466114B2 (en) 2013-06-18
IL219309A0 (en) 2012-06-28
US20150141354A1 (en) 2015-05-21
TW201118104A (en) 2011-06-01
CU24079B1 (en) 2015-03-30
CO6531486A2 (en) 2012-09-28
CL2012000991A1 (en) 2012-09-07
BR112012009053B1 (en) 2020-03-03
UY32958A (en) 2011-05-31
KR20140054415A (en) 2014-05-08
MY158326A (en) 2016-09-30
MA33737B1 (en) 2012-11-01
RS54563B1 (en) 2016-06-30
CA2777812C (en) 2018-07-17
WO2011048112A1 (en) 2011-04-28
KR101465308B1 (en) 2014-11-28
SG179562A1 (en) 2012-05-30
HRP20160436T1 (en) 2016-05-20
NZ598717A (en) 2014-04-30
AR078685A1 (en) 2011-11-23
EP2491029B1 (en) 2016-02-10
KR20120083484A (en) 2012-07-25
JP2013508335A (en) 2013-03-07
SI2491029T1 (en) 2016-05-31
EP2491029A1 (en) 2012-08-29
CA2777812A1 (en) 2011-04-28
CR20120176A (en) 2012-05-22
US8163704B2 (en) 2012-04-24
US20130017993A1 (en) 2013-01-17
TWI594756B (en) 2017-08-11
US20110171159A1 (en) 2011-07-14
USRE49080E1 (en) 2022-05-24
CU20120062A7 (en) 2012-06-29
PE20121281A1 (en) 2012-10-05
TW201632190A (en) 2016-09-16
CN102656165B (en) 2015-02-11
ECSP12011909A (en) 2012-07-31
US20120178680A1 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
JO3152B1 (en) Glycoside derivatives and uses thereof
WO2011048148A3 (en) Glycoside derivative and uses thereof
NZ707859A (en) Inhibitors of sodium glucose cotransporter 1
WO2008144346A3 (en) Crystal structures of sglt2 inhibitors and processes for their preparation
AU2010230585A8 (en) Autotaxin inhibitors
JO2910B1 (en) Organic Compounds
GEP20146003B (en) Benzothiazole derivatives as anticancer agents
EA201100266A1 (en) DIOXA-BICYCLO [3.2.1] OKTAN-2,3,4-TRIOL DERIVATIVES
MY151246A (en) Benzofuranyl derivatives
MX2011012337A (en) Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases.
WO2011056985A3 (en) Substituted heterocyclic compounds
MY165579A (en) Synthetic methods for spiro-oxindole compounds
WO2010029302A3 (en) Compounds for treating viral infections
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
MX2012001413A (en) Novel azaheterocyclic compounds.
MX2011008899A (en) Novel ortho-aminoamides for the treatment of cancer.
ES2333026T3 (en) DERIVED FROM CICLOHEXIL-1,4-DIAMINE SUBSTITUTED.
WO2010018438A3 (en) Tetrazole glycosides
MX2007013872A (en) Process for production of 4-biphenylyazetidin-2-ones.
MX2009009074A (en) Macrolides.
MA32512B1 (en) Phenanthrenone derivatives, compositions and processes
UA109415C2 (en) GLYCOSIDE DERIVATIVES AND THEIR APPLICATIONS
WO2007129184A3 (en) An improved process for the preparation of phenytoin sodium
TN2011000035A1 (en) Organic compounds
NZ613614A (en) Sphingoglycolipid compounds and uses